Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, has received Priority Review from the US FDA for use as a post-neoadjuvant treatment in adult patients with early breast cancer—specifically HER2-positive cases with residual invasive disease after neoadjuvant HER2-targeted therapy. Based on the DESTINY-Breast05 Phase III trial, it showed a 53% reduction in invasive disease recurrence or death risk versus trastuzumab emtansine (T-DM1), with a target action date in Q3 2026. Approval could make it a new standard, tackling unmet needs for patients where half face residual disease and high recurrence.
DESTINY-Breast05 Delivers 53% IDFS Risk Cut vs T-DM1
The DESTINY-Breast05 Phase III trial confirmed Enhertu’s edge, with a 53% drop in invasive disease-free survival (IDFS) events (HR 0.47; 95% CI 0.34-0.66; p<0.0001) over T-DM1, achieving a three-year IDFS rate of 92.4% versus 83.7%. Benefits spanned secondary endpoints: 53% DFS reduction (HR 0.47), 51% lower distant recurrence risk (HR 0.49), and 36% reduced brain metastases risk (HR 0.64). Consistent across subgroups, these results—shared at ESMO 2025 and in the New England Journal of Medicine—could prevent metastatic shift, where survival falls from ~90% to ~30% at five years, impacting ~16,000 US patients yearly in early breast cancer settings.
Trial Design Matches High-Risk HER2 Epidemiology
DESTINY-Breast05 (NCT04622319) randomized 1,635 patients globally with HER2-positive early breast cancer showing residual disease post-neoadjuvant therapy and high recurrence risk (inoperable or node-positive). Participants got Enhertu 5.4 mg/kg or T-DM1, with primary endpoint investigator-assessed IDFS and secondaries like DFS, OS, distant recurrence-free interval, brain metastasis-free interval, and safety. HER2-positive cases (1 in 5 breast cancers) drive aggressive disease; half of neoadjuvant patients have residual disease despite standard care. US stats: >320,000 diagnoses, >42,000 deaths yearly. Enhertu’s safety aligned with prior data, no new signals.
Priority Status Drives HEOR and Access Shifts
Priority Review, plus Breakthrough Therapy tag and Project Orbis for EU/Japan alignment, fast-tracks Enhertu in early breast cancer. It could offset costs via fewer metastases and better survival for 16,000 annual US patients. Enhertu’s metastatic approvals in 90+ countries will bolster payer talks, fueling discussions on recurrence prevention and resource use for sustainable access in high-risk oncology.
